Table 3.

Analysis of associations between GSTM1 and CYP1A1 genotypes and LC risk: crude and adjusted odds ratios and 95% confidence intervals

Groups	GSTM1 genotypesa		CYP1A1 genotypes		Combined GSTM1/CYP1A1 genotypes
	GSTM1(+)	GSTM1(-)	CYP1A1*2 non-carriers	CYP1A1*2 carriers	GSTM1(+) CYP1A1*2 non-carriers	GSTM1(-) CYP1A1*2 non-carriers	GSTM1(+) CYP1A1*2 carriers	GSTM1(-) CYP1A1*2 carriers
Crude ORs
LC versus HD	1.0	0.94 (0.61–1.45)	1.0	1.33 (0.80–2.21)	1.0	1.03 (0.63–1.69)	1.66 (0.78–3.57)	1.15 (0.57–2.30)
LC versus ED	1.0	1.39 (0.92–2.11)	1.0	1.39 (0.85–2.27)	1.0	1.32 (0.82–2.13)	1.26 (0.63–2.46)	2.16 (1.04–4.47)
SCC versus HD	1.0	1.08 (0.62–1.87)	1.0	2.08 (1.14–3.76)	1.0	1.15 (0.59–2.25)	2.49 (0.98–6.16)	2.07 (0.90–4.69)
SCC versus ED	1.0	1.58 (0.92–2.71)	1.0	2.18 (1.21–3.88)	1.0	1.47 (0.76–2.85)	1.88 (0.79–4.32)	3.91 (1.65–9.06)
Non-SCC versus HD	1.0	0.83 (0.48–1.43)	1.0	0.76 (0.36–1.52)	1.0	0.95 (0.52–1.73)	1.09 (0.39–2.88)	0.51 (0.16–1.41)
Non-SCC versus ED	1.0	1.22 (0.72–2.08)	1.0	0.80 (0.39–1.57)	1.0	1.22 (0.68–2.19)	0.83 (0.31–2.02)	0.96 (0.30–2.71)
ORs adjusted for gender and smoking history
LC versus HD	1.0	1.13 (0.68–1.87)	1.0	1.27 (0.70–2.30)	1.0	1.33 (0.75–2.37)	2.06 (0.79–5.41)	1.20 (0.54–2.65)
LC versus ED	1.0	1.54 (0.96–2.48)	1.0	1.37 (0.78–2.40)	1.0	1.58 (0.92–2.71)	1.43 (0.65–3.15)	2.08 (0.92–4.73)
SCC versus HD	1.0	1.25 (0.65–2.41)	1.0	2.22 (1.06–4.63)	1.0	1.51 (0.69–3.30)	3.99 (1.11–14.32)	2.21 (0.84–5.77)
SCC versus ED	1.0	1.79 (0.96–3.35)	1.0	2.27 (1.14–4.52)	1.0	1.78 (0.84–3.78)	2.25 (0.82–6.19)	3.85 (1.43–10.33)
Non-SCC versus HD	1.0	0.97 (0.54–1.73)	1.0	0.72 (0.34–1.55)	1.0	1.17 (0.61–2.24)	1.33 (0.44–4.06)	0.53 (0.17–1.59)
Non-SCC versus ED	1.0	1.32 (0.75–2.30)	1.0	0.80 (0.38–1.66)	1.0	1.41 (0.76–2.61)	0.96 (0.36–2.55)	0.92 (0.30–2.82)

^aGSTM1 genotypes are designated as GSTM1(-) for the null and GSTM1(+) for the non-null